As COVID-19 rapidly evolves, the need for regular updates to booster shots and vaccines becomes increasingly vital to ensure the continued and effective protection of the population against recurrent infections. In this Journal Club, 3 physicians studying infectious disease at Yale School of Medicine discuss the results of a recent paper that reviews the findings of a large, randomized trial of both monovalent and bivalent Omicron-targeted boosters using active control groups and observer blinding.
Special Collections
